229 related articles for article (PubMed ID: 12623855)
1. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Jasmer RM; Daley CL
Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
[No Abstract] [Full Text] [Related]
2. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
3. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
4. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
5. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
[TBL] [Abstract][Full Text] [Related]
6. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
7. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
[No Abstract] [Full Text] [Related]
8. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Lee AM; Mennone JZ; Jones RC; Paul WS
Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
[TBL] [Abstract][Full Text] [Related]
10. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Reichman LB; Lardizabal A; Hayden CH
Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
[No Abstract] [Full Text] [Related]
11. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
[No Abstract] [Full Text] [Related]
12. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
Ijaz K; McElroy PD; Jereb J; Navin TR; Castro KG
Clin Infect Dis; 2007 Feb; 44(3):464-5; author reply 465. PubMed ID: 17205462
[No Abstract] [Full Text] [Related]
13. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
14. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Can Commun Dis Rep; 2001 Jul; 27(13):114-6. PubMed ID: 11443837
[No Abstract] [Full Text] [Related]
15. Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
Medinger A
Chest; 2002 May; 121(5):1710-2. PubMed ID: 12006469
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Kandula NR; Dworkin MS; Carroll MR; Lauderdale DS
Am J Prev Med; 2004 Feb; 26(2):163-6. PubMed ID: 14751331
[TBL] [Abstract][Full Text] [Related]
17. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Cook PP
Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
[No Abstract] [Full Text] [Related]
18. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
19. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
